Revenue ($USD) : $429,909,000
R&D spend : $57,752,000.00
Employees : 1,044
Fiscal year end : 06/30/22
CEO : Suzanne Winter

Accuray specializes in radiation therapy systems to deliver treatments including stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). In 2023, the company said it would join the Russell 2000 and Russell 3000 stock indices. In August, Accuray won FDA 510(k) clearance for its VitalHold breast package to minimize radiation dose when used with its image-guided, intensity-modulated radiation therapy Radixact system. –BB and JH